Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM EV-to-EBITDA is 0.88 as of Aug. 01, 2026. The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, NovelStem International ranks better than 96.64% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NovelStem International's enterprise value is $2.41 Mil.
NovelStem International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2.72 Mil. Therefore, NovelStem International's EV-to-EBITDA for today is 0.88.
The historical rank and industry rank for NovelStem International's EV-to-EBITDA or its related term are showing as below:
NSTM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.88
Current: 0.88
During the past 13 years, the highest EV-to-EBITDA of NovelStem International was 0.88. The lowest was 0.00. And the median was 0.00.
NSTM's EV-to-EBITDA is ranked better than 96.64% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.76
vs NSTM: 0.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NovelStem International (OTCPK:NSTM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovelStem International's PE Ratio (TTM) for today is calculated as:
NovelStem International's share price for today is $0.01146.
NovelStem International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSTM vs NOTVQ, PRPH, IDTA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, NovelStem International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NovelStem International's EV-to-EBITDA falls into.
NovelStem International's current Enterprise Value is $2.41 Mil.
NovelStem International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International (NSTM) has a EV-to-EBITDA of 0.88 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NovelStem International. According to the industry distribution chart, NovelStem International ranks #4 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 3.4%.
Is NovelStem International's EV-to-EBITDA too high?
NovelStem International's current EV-to-EBITDA is 0.88. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.76. NovelStem International's value of 0.88 is 94.4% below this industry median. Based on the distribution chart, NovelStem International ranks #4 out of 119 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does NovelStem International's EV-to-EBITDA compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #4 out of 119 companies for EV-to-EBITDA. This places NovelStem International in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.76. NovelStem International's value of 0.88 is 94.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.76, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovelStem International's current EV-to-EBITDA of 0.88 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NovelStem International. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current EV-to-EBITDA is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current EV-to-EBITDA of 0.88. The current EV-to-EBITDA is 0.88 and 94.4% below the Medical Diagnostics & Research industry median of 15.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NovelStem International (NSTM), the current EV-to-EBITDA is 0.88 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
